Duda Lab
Hong TS, Grassberger C, Yeap BY, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, Dima S, Eyler CE, Popescu I, DeLaney TF, Zhu AX, Duda DG
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy.
NPJ Precis Oncol. 2018;2:22 - PMID: 30374460 - PMCID: PMC6194077 - DOI: 10.1038/s41698-018-0065-y
Lee EQ, Duda DG, Muzikansky A, Gerstner E, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey SC, Batchelor T, Jain RK, Wen PY
Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.
Clin Cancer Res. 2018;24(19):4643-4649 - PMID: 29941486 - DOI: 10.1158/1078-0432.CCR-18-1025
Grassberger C, Hong TS, Hato T, Yeap BY, Wo JY, Tracy M, Bortfeld T, Wolfgang JA, Eyler CE, Goyal L, Clark JW, Crane CH, Koay EJ, Cobbold M, DeLaney TF, Jain RK, Zhu AX, Duda DG
Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer.
Int J Radiat Oncol Biol Phys. 2018;101(5):1222-1225 - PMID: 29859792 - PMCID: PMC6050125 - DOI: 10.1016/j.ijrobp.2018.04.026
Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
Sci Transl Med. 2018;10(432):ePub - PMID: 29540614 - PMCID: PMC5936748 - DOI: 10.1126/scitranslmed.aag0945
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Nat Rev Clin Oncol. 2018;15(5):325-340 - PMID: 29508855 - PMCID: PMC5921900 - DOI: 10.1038/nrclinonc.2018.29
Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, Duda DG, Chen Y
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Theranostics. 2018;8(4):894-905 - PMID: 29463989 - PMCID: PMC5817100 - DOI: 10.7150/thno.21168
6